NASDAQ:NDRA ENDRA Life Sciences (NDRA) Stock Price, News & Analysis $6.01 +0.03 (+0.50%) Closing price 05/7/2025 04:00 PM EasternExtended Trading$5.96 -0.04 (-0.75%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock About ENDRA Life Sciences Stock (NASDAQ:NDRA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ENDRA Life Sciences alerts:Sign Up Key Stats Today's Range$5.95▼$6.1550-Day Range$3.09▼$7.2052-Week Range$2.97▼$602.00Volume26,440 shsAverage Volume133,991 shsMarket Capitalization$3.38 millionP/E RatioN/ADividend YieldN/APrice Target$50.00Consensus RatingBuy Company OverviewENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.Read More… ENDRA Life Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreNDRA MarketRank™: ENDRA Life Sciences scored higher than 50% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingENDRA Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageENDRA Life Sciences has only been the subject of 1 research reports in the past 90 days.Read more about ENDRA Life Sciences' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for ENDRA Life Sciences are expected to grow in the coming year, from ($47.46) to ($15.38) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ENDRA Life Sciences is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ENDRA Life Sciences is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioENDRA Life Sciences has a P/B Ratio of 0.01. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about ENDRA Life Sciences' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.95% of the float of ENDRA Life Sciences has been sold short.Short Interest Ratio / Days to CoverENDRA Life Sciences has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ENDRA Life Sciences has recently increased by 41.46%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldENDRA Life Sciences does not currently pay a dividend.Dividend GrowthENDRA Life Sciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.95% of the float of ENDRA Life Sciences has been sold short.Short Interest Ratio / Days to CoverENDRA Life Sciences has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ENDRA Life Sciences has recently increased by 41.46%, indicating that investor sentiment is decreasing significantly. News and Social Media3.9 / 5News SentimentN/A News SentimentENDRA Life Sciences has a news sentiment score of 1.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for ENDRA Life Sciences this week, compared to 0 articles on an average week.Search Interest3 people have searched for NDRA on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows6 people have added ENDRA Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, ENDRA Life Sciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.04% of the stock of ENDRA Life Sciences is held by insiders.Percentage Held by InstitutionsOnly 1.19% of the stock of ENDRA Life Sciences is held by institutions.Read more about ENDRA Life Sciences' insider trading history. Receive NDRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ENDRA Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address NDRA Stock News HeadlinesENDRA Life Sciences Inc. (NASDAQ:NDRA) Sees Significant Growth in Short InterestMay 3, 2025 | americanbankingnews.comENDRA Life Sciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides a Business UpdateMarch 31, 2025 | finance.yahoo.comYour Wealth is Being Erased – Save It Before It’s Gone ForeverWhat If America's Gold Reserves Are a Lie? For decades, the U.S. government has claimed to have thousands of tons of gold locked away in Fort Knox. But there hasn't been an independent audit in over 50 years—and now, both Elon Musk and former Congressman Ron Paul are demanding answers.May 8, 2025 | Hamilton Gold Group (Ad)ENDRA Life Sciences Announces Enhanced Strategy to Enable the Early Detection and Management of Metabolic Diseases Facilitated by Emerging GLP-1 TherapiesMarch 31, 2025 | businesswire.comENDRA Life Sciences Inc Registered Shs NDRAFebruary 2, 2025 | morningstar.comENDRA Life Sciences Regains Compliance with Nasdaq Minimum Bid Price RequirementNovember 22, 2024 | businesswire.comENDRA Life Sciences Reports Q3 2024 Results and ProgressNovember 16, 2024 | markets.businessinsider.comENDRA Life Sciences Reports Third Quarter 2024 Financial Results and Provides a Business UpdateNovember 15, 2024 | finance.yahoo.comSee More Headlines NDRA Stock Analysis - Frequently Asked Questions How have NDRA shares performed this year? ENDRA Life Sciences' stock was trading at $6.26 at the beginning of the year. Since then, NDRA shares have decreased by 4.0% and is now trading at $6.01. View the best growth stocks for 2025 here. How were ENDRA Life Sciences' earnings last quarter? ENDRA Life Sciences Inc. (NASDAQ:NDRA) issued its earnings results on Monday, March, 31st. The company reported ($9.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($4.10) by $5.30. When did ENDRA Life Sciences' stock split? ENDRA Life Sciences shares reverse split on the morning of Tuesday, August 20th 2024. The 1-50 reverse split was announced on Friday, August 16th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 19th 2024. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. When did ENDRA Life Sciences IPO? ENDRA Life Sciences (NDRA) raised $10 million in an initial public offering (IPO) on Friday, February 3rd 2017. The company issued 2,000,000 shares at a price of $5.00-$5.50 per share. Dougherty & Company and Dawson James Securities acted as the underwriters for the IPO. How do I buy shares of ENDRA Life Sciences? Shares of NDRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ENDRA Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that ENDRA Life Sciences investors own include Bionano Genomics (BNGO), Cocrystal Pharma (COCP), AMC Entertainment (AMC), Plug Power (PLUG), Mustang Bio (MBIO), SNDL (SNDL) and BIOLASE (BIOL). Company Calendar Last Earnings3/31/2025Today5/07/2025Next Earnings (Estimated)5/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Electromedical equipment Sub-IndustryMedical Equipment Current SymbolNASDAQ:NDRA CIK1681682 Webwww.endrainc.com Phone(734) 335-0468FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Stock Price Target$50.00 High Stock Price Target$50.00 Low Stock Price Target$50.00 Potential Upside/Downside+731.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($624.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,060,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-127.39% Return on Assets-103.77% Debt Debt-to-Equity RatioN/A Current Ratio6.10 Quick Ratio6.10 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1,170.18 per share Price / Book0.01Miscellaneous Outstanding Shares562,000Free Float537,000Market Cap$3.38 million OptionableNot Optionable Beta0.19 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free Report This page (NASDAQ:NDRA) was last updated on 5/8/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredTrump to redistribute trillions of dollars Seeing how the media and other analysts are covering Trump’s actions – it’s laughable. At least it would be la...Porter & Company | Sponsored270x more lucrative than NVIDIA???270x more lucrative than NVIDIA??? If you've missed out on NVIDIA's recent 1,600% run... Don't worry. ...Behind the Markets | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredVanishing BenefitsWhat would you do if your next Social Security check simply never arrived? If you called and the line was d...Investors Alley | SponsoredSilver’s 332% Surge?Silver has quietly become one of the most promising investments of this cycle. Russia is now stockpiling silve...Lear Capital | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ENDRA Life Sciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ENDRA Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.